BDBM50434787 CHEMBL2386635::US10487083, Example C::US10703751, Example 644 of WO2011086053::US11059823, Example C
SMILES C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1
InChI Key InChIKey=IKSRDHMMQOCRHN-JHJVBQTASA-N
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 20 hits for monomerid = 50434787
Affinity DataKi: 0.100nMAssay Description:Inhibition of recombinant JAK1 (unknown origin) using Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr as substrate after 30 mins in presence of ATPMore data for this Ligand-Target Pair
3D Structure (crystal)Affinity DataKi: 5.90nMAssay Description:Inhibition of JAK3 (unknown origin) using Leu-Pro-Leu-Asp-Lys-Asp-Tyr-Tyr-Val-Val-Arg as substrate after 30 mins in presence of ATPMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:Reversible inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate by LC/MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:Reversible inhibition of CYP2C19 in human liver microsomes using mephenytoin as substrate by LC/MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:Reversible inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate by LC/MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:Reversible inhibition of CYP2C9 in human liver microsomes using warfarin as substrate by LC/MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: <0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Affinity DataIC50: 49.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Affinity DataEC50: 0.340nMAssay Description:Human baculovirus-expressed Janus kinase (JAK) 1, 2, 3 and tyrosin kinase (TYK) 2 were purchased from Carna Biosciences, Inc (#08-144, -045, -046, -1...More data for this Ligand-Target Pair
Affinity DataEC50: 3.34nMAssay Description:Human baculovirus-expressed Janus kinase (JAK) 1, 2, 3 and tyrosin kinase (TYK) 2 were purchased from Carna Biosciences, Inc (#08-144, -045, -046, -1...More data for this Ligand-Target Pair
Affinity DataEC50: 13.1nMAssay Description:Human baculovirus-expressed Janus kinase (JAK) 1, 2, 3 and tyrosin kinase (TYK) 2 were purchased from Carna Biosciences, Inc (#08-144, -045, -046, -1...More data for this Ligand-Target Pair
Affinity DataEC50: 3.32nMAssay Description:Human baculovirus-expressed Janus kinase (JAK) 1, 2, 3 and tyrosin kinase (TYK) 2 were purchased from Carna Biosciences, Inc (#08-144, -045, -046, -1...More data for this Ligand-Target Pair
Affinity DataIC50: <0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Affinity DataIC50: 49.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Affinity DataEC50: 28nMAssay Description:Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins followed by IL6 challenge for...More data for this Ligand-Target Pair
Affinity DataEC50: 5.70nMAssay Description:Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins followed by IL6 challenge for...More data for this Ligand-Target Pair